Cargando…

Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group

OBJECTIVES: To compare the predictive performance and potential clinical usefulness of risk calculators of the European Randomized Study of Screening for Prostate Cancer (ERSPC RC) with and without information on prostate volume. METHODS: We studied 6 cohorts (5 European and 1 US) with a total of 15...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roobol, Monique J., Schröder, F. H., Hugosson, Jonas, Jones, J. Stephen, Kattan, Michael W., Klein, Eric A., Hamdy, Freddie, Neal, David, Donovan, Jenny, Parekh, Dipen J., Ankerst, Donna, Bartsch, George, Klocker, Helmut, Horninger, Wolfgang, Benchikh, Amine, Salama, Gilles, Villers, Arnauld, Freedland, Stephen J., Moreira, Daniel M., Vickers, Andrew J., Lilja, Hans, Steyerberg, Ewout W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2011
Materias:	Topic Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3321270/ https://www.ncbi.nlm.nih.gov/pubmed/22203238 http://dx.doi.org/10.1007/s00345-011-0804-y

Ejemplares similares

A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France
por: Benchikh, Amine, et al.
Publicado: (2010)

The Patient Journey from Randomization to Detection of Prostate Cancer and Death: Results from ERSPC Rotterdam
por: Remmers, Sebastiaan, et al.
Publicado: (2023)

Prostate Cancer Mortality in Areas With High and Low Prostate Cancer Incidence
por: Stattin, Pär, et al.
Publicado: (2014)

Personalized schedules for surveillance of low‐risk prostate cancer patients
por: Tomer, Anirudh, et al.
Publicado: (2018)

Secondary Treatment for Men with Localized Prostate Cancer: A Pooled Analysis of PRIAS and ERSPC-Rotterdam Data within the PIONEER Data Platform †
por: Beyer, Katharina, et al.
Publicado: (2022)

A Tool for Shared Decision Making on Referral for Prostate Biopsy in the Primary Care Setting: Integrating Risks of Cancer with Life Expectancy
por: Verbeek, Jan F.M., et al.
Publicado: (2019)

Multi-cohort modeling strategies for scalable globally accessible prostate cancer risk tools
por: Tolksdorf, Johanna, et al.
Publicado: (2019)

Association of Baseline Prostate-Specific Antigen Level With Long-term Diagnosis of Clinically Significant Prostate Cancer Among Patients Aged 55 to 60 Years: A Secondary Analysis of a Cohort in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial
por: Kovac, Evan, et al.
Publicado: (2020)

Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study
por: Carlsson, Sigrid, et al.
Publicado: (2014)

Personalized Decision Making for Biopsies in Prostate Cancer Active Surveillance Programs
por: Tomer, Anirudh, et al.
Publicado: (2019)

Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen
por: Vickers, Andrew J, et al.
Publicado: (2014)

Accommodating heterogeneous missing data patterns for prostate cancer risk prediction
por: Neumair, Matthias, et al.
Publicado: (2022)

Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008
por: Oberaigner, Willi, et al.
Publicado: (2011)

Methods to Predict and Lower the Risk of Prostate Cancer
por: Ercole, Barbara, et al.
Publicado: (2011)

A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer Screening in Rotterdam, Netherlands
por: Gupta, A, et al.
Publicado: (2010)

Aspirin and prostate cancer prevention
por: Vidal, Adriana C., et al.
Publicado: (2015)

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden
por: Vickers, Andrew J, et al.
Publicado: (2008)

Active surveillance for prostate cancer
por: Shill, Daniela K., et al.
Publicado: (2021)

Personalised biopsy schedules based on risk of Gleason upgrading for patients with low‐risk prostate cancer on active surveillance
por: Tomer, Anirudh, et al.
Publicado: (2020)

Comparison of Proclarix, PSA Density and MRI-ERSPC Risk Calculator to Select Patients for Prostate Biopsy after mpMRI
por: Campistol, Miriam, et al.
Publicado: (2022)

Age-Adjusted PSA Levels in Prostate Cancer Prediction: Updated Results of the Tyrol Prostate Cancer Early Detection Program
por: Heidegger, Isabel, et al.
Publicado: (2015)

Rule-based versus probabilistic selection for active surveillance using three definitions of insignificant prostate cancer
por: Venderbos, Lionne D. F., et al.
Publicado: (2015)

Intervention-related Deaths in the European Randomized Study of Screening for Prostate Cancer
por: Godtman, Rebecka Arnsrud, et al.
Publicado: (2021)

Benefits and harms of prostate cancer screening – predictions of the ONCOTYROL prostate cancer outcome and policy model
por: Mühlberger, Nikolai, et al.
Publicado: (2017)

Improving prediction models with new markers: a comparison of updating strategies
por: Nieboer, D., et al.
Publicado: (2016)

Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer
por: Schaefer, G, et al.
Publicado: (2013)

5-alpha-reductase and the development of the human prostate
por: Radmayr, C., et al.
Publicado: (2008)

Editorial Comment: A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer
por: Hugosson, J, et al.
Publicado: (2020)

Nutrition, dietary interventions and prostate cancer: the latest evidence
por: Lin, Pao-Hwa, et al.
Publicado: (2015)

Focal therapy for localized prostate cancer – Current status
por: Atluri, Shrikanth, et al.
Publicado: (2022)

Impact of cause of death adjudication on the results of the European prostate cancer screening trial
por: Walter, Stephen D, et al.
Publicado: (2017)

Prostate cancer-specific anxiety in Dutch patients on active surveillance: validation of the memorial anxiety scale for prostate cancer
por: van den Bergh, Roderick C. N., et al.
Publicado: (2009)

Imaging for Metastasis in Prostate Cancer: A Review of the Literature
por: Turpin, Anthony, et al.
Publicado: (2020)

5-α reductase inhibitors and prostate cancer prevention: where do we turn now?
por: Hamilton, Robert J, et al.
Publicado: (2011)

Re: Commentary on “The association between sexual function and prostate cancer risk in US veterans”
por: Vidal, Adriana C, et al.
Publicado: (2018)

Multiparametric MRI-Targeted TRUS Prostate Biopsies Using Visual Registration
por: Puech, Philippe, et al.
Publicado: (2014)

Novel therapeutic approaches for the treatment of castration-resistant prostate cancer()
por: Heidegger, Isabel, et al.
Publicado: (2013)

Screening for prostate cancer: are organized screening programs necessary?
por: Roobol, Monique J.
Publicado: (2018)

Prostate cancer screening and active surveillance in the Western world
por: Roobol, Monique J.
Publicado: (2018)

Novel biomarkers for the detection of prostate cancer
por: Jakobsen, Niels Asger, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_t9h4mlekapr5ruht9mqgk4pj3f